Bita Fakhri

15PUBLICATIONS
83CO-AUTHORS
Molecular targetsHaematological tumoursCardiology (incl. cardiovascular diseases)Cancer therapy (excl. chemotherapy and radiation therapy)Counselling, wellbeing and community services
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jan 26, 2026
Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.

Michal Sekrecki, Agata Sekrecka, Rohan R Lattupally

|Jan 16, 2026
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Krish Patel, Julie M Vose, Sunita D Nasta

|Nov 11, 2025
Clinical profiles of chronic lymphocytic leukaemia patients with SF3B1 mutations: A single-institution study.

Bita Fakhri, Rohan Lattupally, Kyaw Sint

|Aug 22, 2025
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.

Nirav N Shah, Pier Luigi Zinzani, Michael Wang

|Mar 11, 2025
Consensus in CLL: global needs matter.

Mazyar Shadman, Bita Fakhri, Nitin Jain

|Sep 02, 2024
Pericardial events associated with ibrutinib-based therapies for chronic lymphocytic leukaemia in two landmark trials.

Bita Fakhri, Victoria Wang, Gabriela Perez-Burbano

Pageof 3

Frequent Collaborators

3 joint publications

Jonathon B Cohen

3 joint publications

John N Allan

2 joint publications

Jennifer Woyach

2 joint publications

Chaitra Ujjani